A Promising Needle-Free Pyro-Drive Jet Injector for Augmentation of Immunity by Intradermal Injection as a Physical Adjuvant.

COVID-19 CTL generation SARS-CoV-2 antibody production intradermal injection needle-free injector pyro-drive jet injector shear stress vaccine

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
22 May 2023
Historique:
received: 07 04 2023
revised: 08 05 2023
accepted: 17 05 2023
medline: 29 5 2023
pubmed: 27 5 2023
entrez: 27 5 2023
Statut: epublish

Résumé

Current worldwide mRNA vaccination against SARS-CoV-2 by intramuscular injection using a needled syringe has greatly protected numerous people from COVID-19. An intramuscular injection is generally well tolerated, safer and easier to perform on a large scale, whereas the skin has the benefit of the presence of numerous immune cells, such as professional antigen-presenting dendritic cells. Therefore, intradermal injection is considered superior to intramuscular injection for the induction of protective immunity, but more proficiency is required for the injection. To improve these issues, several different types of more versatile jet injectors have been developed to deliver DNAs, proteins or drugs by high jet velocity through the skin without a needle. Among them, a new needle-free pyro-drive jet injector has a unique characteristic that utilizes gunpower as a mechanical driving force, in particular, bi-phasic pyrotechnics to provoke high jet velocity and consequently the wide dispersion of the injected DNA solution in the skin. A significant amount of evidence has revealed that it is highly effective as a vaccinating tool to induce potent protective cellular and humoral immunity against cancers and infectious diseases. This is presumably explained by the fact that shear stress generated by the high jet velocity facilitates the uptake of DNA in the cells and, consequently, its protein expression. The shear stress also possibly elicits danger signals which, together with the plasmid DNA, subsequently induces the activation of innate immunity including dendritic cell maturation, leading to the establishment of adaptive immunity. This review summarizes the recent advances in needle-free jet injectors to augment the cellular and humoral immunity by intradermal injection and the possible mechanism of action.

Identifiants

pubmed: 37240448
pii: ijms24109094
doi: 10.3390/ijms24109094
pmc: PMC10219147
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan
ID : 22K12772
Organisme : Daicel Corporation
ID : No number

Références

Int J Pharm. 2023 Feb 5;632:122559
pubmed: 36586639
Gene Ther. 2006 Dec;13(23):1619-27
pubmed: 16871232
Risk Manag Healthc Policy. 2021 May 20;14:2079-2087
pubmed: 34045909
Immunol Med. 2022 Dec;45(4):251-264
pubmed: 36001011
Am J Ind Med. 2005 Dec;48(6):482-90
pubmed: 16299710
Med Eng Phys. 2012 Nov;34(9):1228-35
pubmed: 22245386
Clin Cosmet Investig Dermatol. 2018 May 01;11:231-238
pubmed: 29750049
Front Immunol. 2023 Jan 19;14:1105655
pubmed: 36742311
Crit Rev Immunol. 1998;18(5):389-418
pubmed: 9784967
Immunity. 2005 Aug;23(2):165-75
pubmed: 16111635
Vaccine. 2013 Jul 25;31(34):3392-5
pubmed: 23176978
PLoS One. 2015 Mar 20;10(3):e0120586
pubmed: 25793984
JAMA. 2021 Oct 12;326(14):1390-1399
pubmed: 34477808
FASEB J. 2020 Mar;34(3):3485-3500
pubmed: 31994227
J Allergy Clin Immunol. 2008 Jun;121(6):1331-6
pubmed: 18539191
Nature. 1998 Mar 19;392(6673):245-52
pubmed: 9521319
Nature. 2021 Sep;597(7876):318-324
pubmed: 34522017
JAMA Netw Open. 2021 Feb 1;4(2):e2035693
pubmed: 33560425
Nat Rev Immunol. 2021 Oct;21(10):626-636
pubmed: 34373623
J Exp Med. 2008 Apr 14;205(4):869-82
pubmed: 18362170
iScience. 2021 Dec 17;24(12):103479
pubmed: 34841223
Nat Med. 2021 Dec;27(12):2144-2153
pubmed: 34697502
J Leukoc Biol. 2000 Dec;68(6):793-806
pubmed: 11129646
Pharmacol Rev. 2017 Apr;69(2):200-235
pubmed: 28356439
Nat Commun. 2018 Sep 12;9(1):3695
pubmed: 30209303
Sci Rep. 2022 Dec 3;12(1):20923
pubmed: 36463322
Pharmaceutics. 2022 Aug 25;14(9):
pubmed: 36145531
Hum Vaccin Immunother. 2016 Aug 2;12(8):2025-2028
pubmed: 27003336
Int J Pharm. 2021 Nov 20;609:121200
pubmed: 34662643
Biotechnol Bioeng. 2008 Mar 1;99(4):846-54
pubmed: 17879304
AAPS PharmSciTech. 2019 Dec 9;21(1):19
pubmed: 31820256
Hum Vaccin Immunother. 2021 Dec 2;17(12):5255-5268
pubmed: 34582315
J Gene Med. 2000 Mar-Apr;2(2):76-88
pubmed: 10809141
Adv Sci (Weinh). 2021 Aug;8(15):e2004595
pubmed: 34096197
J Invest Dermatol. 2020 Sep;140(9):1794-1804.e4
pubmed: 32035094
Immune Netw. 2015 Apr;15(2):51-7
pubmed: 25922593
Adv Ther. 2017 Jan;34(1):252-260
pubmed: 27928757
Trends Mol Med. 2022 Jul;28(7):542-554
pubmed: 35537987
Eur J Pediatr. 1994 Jun;153(6):409-10
pubmed: 8088294
Vaccines (Basel). 2022 Aug 30;10(9):
pubmed: 36146505
Biotechnol Bioeng. 2000 Jun 20;68(6):697-704
pubmed: 10799996
Cell Rep. 2020 Nov 24;33(8):108433
pubmed: 33238123
Nature. 2020 May;581(7807):221-224
pubmed: 32225175
Future Virol. 2021 Nov;:
pubmed: 34858516
PLoS One. 2014 Jun 09;9(6):e99677
pubmed: 24911341
J Pharm Sci. 2019 Jul;108(7):2415-2420
pubmed: 30849461
Exp Dermatol. 2016 Feb;25(2):92-8
pubmed: 26284579
Toxicology. 2002 Dec 27;181-182:311-5
pubmed: 12505331
J Pharm Sci. 2021 Mar;110(3):1310-1315
pubmed: 33253725
Mol Ther. 2017 Dec 6;25(12):2635-2647
pubmed: 28958578
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Nat Rev Cardiol. 2020 Jan;17(1):52-63
pubmed: 31366922
J Biomed Sci. 2014 Jan 13;21:3
pubmed: 24410814
Semin Immunol. 2003 Oct;15(5):257-70
pubmed: 15001175
Trends Biochem Sci. 2021 May;46(5):351-365
pubmed: 33309323
Curr Res Transl Med. 2022 Sep;70(4):103348
pubmed: 35489099
J Cosmet Dermatol. 2021 Dec;20(12):3793-3801
pubmed: 33682249
Vaccines (Basel). 2020 Sep 16;8(3):
pubmed: 32947966
N Engl J Med. 2021 Sep 16;385(12):1078-1090
pubmed: 34432976
Gene. 2021 Jul 1;788:145664
pubmed: 33887371
J Adv Nurs. 2019 Jan;75(1):30-42
pubmed: 30109720
Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):2082-7
pubmed: 23341631
Signal Transduct Target Ther. 2021 Aug 4;6(1):291
pubmed: 34344870
J Med Microbiol. 2012 Jul;61(Pt 7):927-934
pubmed: 22174375
FEBS Open Bio. 2023 Mar;13(3):478-489
pubmed: 36651034
Nat Rev Immunol. 2017 Jan;17(1):30-48
pubmed: 27890914
Curr Top Microbiol Immunol. 2012;351:159-79
pubmed: 21416266
Annu Rev Biochem. 1986;55:663-700
pubmed: 2874766
Adv Drug Deliv Rev. 2022 Mar;182:114109
pubmed: 34998902
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Cancer Sci. 2023 Jan;114(1):34-47
pubmed: 36000926
J Interferon Cytokine Res. 2021 Nov;41(11):391-406
pubmed: 34788131
Life Sci. 2021 Feb 15;267:118919
pubmed: 33352173
Phys Rev E Stat Nonlin Soft Matter Phys. 2010 Nov;82(5 Pt 1):051602
pubmed: 21230483

Auteurs

Jukito Sonoda (J)

Department of Immunoregulation, Institute of Medical Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan.

Izuru Mizoguchi (I)

Department of Immunoregulation, Institute of Medical Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan.

Shinya Inoue (S)

Department of Immunoregulation, Institute of Medical Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan.

Aruma Watanabe (A)

Department of Immunoregulation, Institute of Medical Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan.

Ami Sekine (A)

Department of Immunoregulation, Institute of Medical Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan.

Miu Yamagishi (M)

Department of Immunoregulation, Institute of Medical Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan.

Satomi Miyakawa (S)

Department of Immunoregulation, Institute of Medical Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan.

Natsuki Yamaguchi (N)

Department of Immunoregulation, Institute of Medical Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan.

Eri Horio (E)

Department of Immunoregulation, Institute of Medical Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan.

Yasuhiro Katahira (Y)

Department of Immunoregulation, Institute of Medical Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan.

Hideaki Hasegawa (H)

Department of Immunoregulation, Institute of Medical Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan.

Takashi Hasegawa (T)

Department of Device Application for Molecular Therapeutics, Graduate School of Medicine, Osaka University, CoMIT 0603, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan.

Kunihiko Yamashita (K)

Department of Device Application for Molecular Therapeutics, Graduate School of Medicine, Osaka University, CoMIT 0603, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan.

Takayuki Yoshimoto (T)

Department of Immunoregulation, Institute of Medical Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH